Quassin
Based on 1 Customer Validation
Quassin (Nigakilactone D) is a bioactive triterpenoid from stem bark extract of Quassia amara. Quassin inhibits P. falciparum with an IC50 of 0.15 μM. Quassin possesses reversible antifertility, anti-estrogenic and anti-plasmodial activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.0%
- CAS No.: 76-78-8
- Formule: C22H28O6
- Masse moléculaire:388.45
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Covalent Screening Library
HY-L036
-
Lipid Compound Library
HY-L043
-
Endocrinology Compound Library
HY-L047
-
Medicine Food Homology Compound Library
HY-L055
-
Terpenoids Library
HY-L056
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Antiparasitic Compound library
HY-L082
-
Plant-Sourced Natural Product Library
HY-L115
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Natural Product Library Plus
HY-L021P
-
Bioactive Compound Library
HY-L001
-
Tibetan Medicine Compound Library
HY-L191
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Anti-Infection Compound Library
HY-L002
-
Natural Product Library
HY-L021
Voir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
|
Plasmodium |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
>2 μM
Compound: 11
|
Inhibition of protein synthesis in human HeLa cells assessed as [35S]methionine incorporation into protein treated for 45 mins before [35S]methionine addition by Whatman paper analysis
Inhibition of protein synthesis in human HeLa cells assessed as [35S]methionine incorporation into protein treated for 45 mins before [35S]methionine addition by Whatman paper analysis
|
[PMID: 19199792] |
| KB | IC50 |
911 μM
Compound: 1
|
Cytotoxicity against human KB cells by microplate method
Cytotoxicity against human KB cells by microplate method
|
[PMID: 14640524] |
Quassin (Compound 1; 5-25 ng/mL) inhibits both the basal and luteinizing hormone-stimulated testosterone secretion of rat Leydig cells in a dose-dependent fashion[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:35 females albino rats (150-170 g)[1]
-
Dosage:0.1 mg/kg, 1.0 mg/kg and 2.0 mg/kg
-
Administration:Oral administration; daily; for 60 days
-
Result:There was a significant decrease in the weight of the ovary and uterus in all the groups relative to the control. There was also a significant decrease in serum estrogen levels in quassin treated rats.
Chemical Information
-
CAS No. 76-78-8
-
Appearance Solid
-
Masse moléculaire 388.45
-
Formule C22H28O6
-
Color White to off-white
-
SMILES
C[C@@H]([C@@]1(C[C@]2(OC(C[C@]([C@]2([C@]3([C@@]41C)[H])C)(C(C)=C(OC)C3=O)[H])=O)[H])[H])C=C(OC)C4=O
-
Synonyms
Nigakilactone D
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
DMSO : 100 mg/mL (257.43 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (291 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Raji Y, et al. Reproductive activities of female albino rats treated with quassin, a bioactive triterpenoid from stem bark extract of Quassia amara. Niger J Physiol Sci. 2010 Nov 24;25(2):95-102. [Content Brief]
[2]. Mishra K, et al. Plasmodium falciparum: in vitro interaction of quassin and neo-quassin with artesunate, a hemisuccinate derivative of artemisinin. Exp Parasitol. 2010 Apr;124(4):421-7. [Content Brief]
[3]. Njar VC, et al. Antifertility activity of Quassia amara: quassin inhibits the steroidogenesis in rat Leydig cells in vitro. Planta Med. 1995 Apr;61(2):180-2. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5743 mL | 12.8717 mL | 25.7433 mL | 64.3583 mL |
| 5 mM | 0.5149 mL | 2.5743 mL | 5.1487 mL | 12.8717 mL | |
| 10 mM | 0.2574 mL | 1.2872 mL | 2.5743 mL | 6.4358 mL | |
| 15 mM | 0.1716 mL | 0.8581 mL | 1.7162 mL | 4.2906 mL | |
| 20 mM | 0.1287 mL | 0.6436 mL | 1.2872 mL | 3.2179 mL | |
| 25 mM | 0.1030 mL | 0.5149 mL | 1.0297 mL | 2.5743 mL | |
| 30 mM | 0.0858 mL | 0.4291 mL | 0.8581 mL | 2.1453 mL | |
| 40 mM | 0.0644 mL | 0.3218 mL | 0.6436 mL | 1.6090 mL | |
| 50 mM | 0.0515 mL | 0.2574 mL | 0.5149 mL | 1.2872 mL | |
| 60 mM | 0.0429 mL | 0.2145 mL | 0.4291 mL | 1.0726 mL | |
| 80 mM | 0.0322 mL | 0.1609 mL | 0.3218 mL | 0.8045 mL | |
| 100 mM | 0.0257 mL | 0.1287 mL | 0.2574 mL | 0.6436 mL |
Quassin Related Classifications
HY-N1581 Related Classifications
Powered by Bioz